Innovus Pharmaceuticals (OTCMKTS:INNV) vs. Tonix Pharmaceuticals (TNXP) Head to Head Contrast

Innovus Pharmaceuticals (OTCMKTS: INNV) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Volatility & Risk

Innovus Pharmaceuticals has a beta of 3.32, meaning that its share price is 232% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.62, meaning that its share price is 162% more volatile than the S&P 500.

Profitability

This table compares Innovus Pharmaceuticals and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovus Pharmaceuticals -102.95% -330.39% -72.75%
Tonix Pharmaceuticals N/A -78.25% -73.14%

Earnings and Valuation

This table compares Innovus Pharmaceuticals and Tonix Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innovus Pharmaceuticals $4.82 million 3.75 -$13.70 million ($0.06) -1.83
Tonix Pharmaceuticals N/A N/A -$38.84 million ($3.38) -1.13

Innovus Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals. Innovus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

17.6% of Tonix Pharmaceuticals shares are held by institutional investors. 19.1% of Innovus Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Innovus Pharmaceuticals and Tonix Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovus Pharmaceuticals 0 0 0 0 N/A
Tonix Pharmaceuticals 0 0 4 0 3.00

Tonix Pharmaceuticals has a consensus target price of $8.33, indicating a potential upside of 118.72%. Given Tonix Pharmaceuticals’ higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Innovus Pharmaceuticals.

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply